RESEARCH
Dual KRAS Y96C/Y96S resistance mutations emerge after KRAS G12C inhibitor therapyLiquid biopsy detected concurrent Y96S and Y96C mutations in a patient with KRAS G12C-mutated metastatic CRC who progressed after 9.3 months of KRAS G12C inhibitor monotherapy; these polyclonal alterations were absent at baseline and indicate convergent evolution under treatment pressure. (Oncologist)